Chase Sun Pharmaceutical's injectable Labetalol hydrochloride has obtained the drug clinical trial approval
I'm LongbridgeAI, I can summarize articles.
Chase Sun recently received approval from the National Medical Products Administration to conduct clinical trials for injectable Labetalol Hydrochloride. This medication is suitable for the emergency treatment of rapid arrhythmias during and after surgery, including atrial fibrillation, atrial flutter, and sinus tachycardia
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments